LEADING THE WAY IN ANTI-CANCER DRUG DISCOVERY & DEVELOPMENT

Over the past several decades, Taiho has had a successful track record of producing anti-cancer treatments. These successes have brought us to where we are today, with a strong vision to lead the charge in combining conventional and targeted agents. Our unique two-pronged approach of continuously leveraging expertise in anti-metabolite therapies while also combining them with molecular targeted agents, has uncovered a wide range of promising treatments for the future.

STUDIES BASED IN NORTH AMERICA

For a full listing of all Taiho studies globally, please click here.

Filter view:
P
Preclinical
1
Phase 1
2
Phase 2
3
Phase 3
S
Submitted
F
Filed
Compounds Ind
Code
Indications
Location
Phase
TAS-114
SOLID TUMORS
US, EU
P
1
2

TAS-114 is an inhibitor of dUTPase, a gatekeeper protein in pyrimidine-metabolism. It is a fluoropyrimidine modulator with the potential to increase the activity of 5-FU-based anti-cancer drugs. It is being developed in combination with S-1 and capecitabine.

Link to clinicaltrials.gov

TAS-102
GASTRIC CANCER
US, EU, JP
P
1
2
3

TAS-102 is a combination of trifluridine, a thymidine based nucleoside anti-neoplastic agent, and tipiracil, a thymidine phosphorylase inhibitor.

Link to clinicaltrials.gov

TAS-119
SOLID TUMORS
US, EU
P
1

TAS-119 is a highly selective Aurora A inhibitor (selective over Aurora B & C). TAS-119 has the potential to enhance anti-tumor activity of taxanes through activation of the spindle assembly checkpoint.

Link to clinicaltrials.gov

TAS-120
SOLID TUMORS
US, EU, JP
P
1
2

TAS-120 is the first covalent FGFR inhibitor that will be tested in clinic and has the potential to selectively inhibit tumor growth of cancer cells with FGFR abnormalities.

Link to clinicaltrials.gov

TAS3681
SOLID TUMORS-MCRPC
US, EU
P
1

TAS3681, a pure AR antagonist, is specifically designed to address the unmet medical need in CRPC patients by combining known mechanisms of action with novel ones:

  • A selective AR antagonist suppressing transactivation of both wild-type and mutated (including F876L) cell lines and inhibiting AR translocation to the nucleus
  • Downregulating AR expression in prostate cancer cells in vitro and in vivo and effectively suppressing androgen independent AR transactivation by outlaw pathways
  • Driving AR downregulation of full-length androgen receptor (FL-AR) and AR splice variants (eg, AR-v7) in vitro and in vivo, and suppressing AR dependent and AR-v7 dependent cell growth

Link to clinicaltrials.gov

TAS4464
SOLID TUMORS, HEMATOLOGICAL CANCER
US, EU & JP
P
1

TAS4464 is a highly potent and selective NEDD8 activating enzyme inhibitor. TAS4464 has the potential to demonstrate antitumor activity through the accumulation of cullin RING ligase substrates.

Link to clinicaltrials.gov

TAS-116
SOLID TUMORS
US, EU
P
1

TAS-116 is a highly potent oral HSP90 inhibitor with unique tissue distribution properties. TAS-116 has the potential to demonstrate antitumor activity, while being designed to limit certain adverse events by unique tissue distribution.

Link to clinicaltrials.gov

TAS0728
SOLID TUMORS
US, EU
P
1

TAS0728 is an orally available, small molecule, HER2 selective covalent inhibitor. TAS0728 inhibits HER2 kinase activity while sparing wild type EGFR kinase inhibition.

Link to clinicaltrials.gov

P
Preclinical
1
Phase 1
2
Phase 2
3
Phase 3
S
Submitted
F
Filed

PLEASE NOTE: all data is current as of June 30, 2018

* This material contains information regarding investigational agents that, unless otherwise indicated have not been approved for commercial use by any country's Regulatory Authority. In addition, the clinical efficacy and safety for these investigational agents has not been established. There is no guarantee that these compounds will become commercially available or proven safe and effective for any particular therapeutic indication.

Taiho Logo

Success!

Job description sent to

Success!

Event sent to

Success!

News Release sent to